Trend: Bullish structure with moving averages aligned (SMA_5 > SMA_20 > SMA_200) and MACD histogram positive and expanding (momentum still up).
Overbought risk: RSI_6 at ~79.4 indicates a stretched short-term condition (pullback risk elevated).
Key levels: Pivot 140.53 (current post-market ~140.37 is just below), resistance R1 144.60 then R2 147.12; supports S1 136.46 then S2 133.94.
Near-term pattern stats provided: ~50% chance of -0.88% next day and -0.63% next week, with a modest +1.72% 1-month bias—suggesting choppy consolidation is likely before another leg up.
Activity: Today’s options volume is ~23.28x the 30-day average (event-driven spike around earnings).
Volatility/pricing: 30D IV ~30.96 vs historical vol ~17.16 (options priced rich); IV percentile ~75.7 suggests elevated implied volatility conditions.
Interpretation: Options markets lean bullish, but elevated IV means upside exposure is expensive and post-event volatility crush is possible.
Technical Summary
Sell
2
Buy
9
Positive Catalysts
Earnings growth: Q4 2025 net income reported up ~9.3% YoY (headline improvement year-over-year).
Regulatory overhang narrative (per analysts): DoJ/SEC inquiries resolved with no enforcement actions (helps multiple expansion case).
Macro tailwind (per Morgan Stanley): lower interest rates + steady equity markets could support sector fundamentals.
Conference call Feb 5, 2026: potential to clarify outlook and re-rate if guidance/2026 commentary is strong.
Neutral/Negative Catalysts
increases odds of a pullback toward 136–134 support before a cleaner entry.
Financial Performance
Latest quarter (Q4 2025, reported 2026-02-04): net income per diluted share reported around $3.29–$3.39 (sources provided), up ~9.3% YoY, but slightly below consensus (3.39 vs 3.44 est).
Prior quarter snapshot (2025/Q3): Revenue $1.512B (+3.96% YoY), Net Income $387.8M (+28% YoY), EPS $4.73 (+37.5% YoY) — strong profitability and earnings power trend.
Overall: fundamentals appear steady-to-strong, but the market is currently focused on the earnings miss and near-term positioning/flows.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent tone: mostly constructive. TD Cowen reaffirmed Buy and raised PT to $199 (from $182) and called it a top pick/Best Idea for 2026.
Morgan Stanley kept Overweight but nudged PT slightly down ($179→$177→$176 across updates), implying bullish stance with minor valuation/assumption tweaks.
Wall Street pros: steady top-line growth, strong profitability/execution, regulatory overhang largely behind, valuation seen below historical averages (per TD Cowen).
Wall Street cons: sensitivity to macro/rates assumptions and the market’s short-term disappointment around the latest print; targets imply upside, but near-term tape is less supportive given selling by insiders/hedge funds.
Wall Street analysts forecast GL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 170.88 USD with a low forecast of 155 USD and a high forecast of 199 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast GL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 170.88 USD with a low forecast of 155 USD and a high forecast of 199 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 146.950
Low
155
Averages
170.88
High
199
Current: 146.950
Low
155
Averages
170.88
High
199
JPMorgan
Jimmy Bhullar
maintain
$180 -> $181
AI Analysis
2026-02-05
New
Reason
JPMorgan
Jimmy Bhullar
Price Target
$180 -> $181
AI Analysis
2026-02-05
New
maintain
Reason
JPMorgan analyst Jimmy Bhullar raised the firm's price target on Globe Life to $181 from $180 and keeps an Overweight rating on the shares.
Morgan Stanley
Bob Huang
Overweight
downgrade
$177 -> $176
2025-12-15
Reason
Morgan Stanley
Bob Huang
Price Target
$177 -> $176
2025-12-15
downgrade
Overweight
Reason
Morgan Stanley analyst Bob Huang lowered the firm's price target on Globe Life to $176 from $177 and keeps an Overweight rating on the shares. Lower interest rates and a steady or better equity market should serve as the broader macro backdrops and 2026 should see "similar fundamental trends as 2025," the analyst tells investors in a life insurance group outlook note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GL
